Details of the Drug Combination

General Information of Drug Combination (ID: DCKVELM)

Drug Combination Name
BIO-300 Amonafide
Indication
Disease Entry Status REF
Lung adenocarcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Amonafide   DMAH59S
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: EKVX
Zero Interaction Potency (ZIP) Score: 1.49
Bliss Independence Score: 3.93
Loewe Additivity Score: 3.03
LHighest Single Agent (HSA) Score: 8.12

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DC2XRPS HL-60(TB) Investigative [5]
Anaplastic large cell lymphoma DCFWU2Y SR Investigative [5]
Astrocytoma DCL4WO5 SNB-19 Investigative [5]
Chronic myelogenous leukemia DC36X6W K-562 Investigative [5]
Clear cell renal cell carcinoma DC1G5G5 786-0 Investigative [5]
Clear cell renal cell carcinoma DCU4X53 TK-10 Investigative [5]
Glioblastoma DCHAS80 SNB-75 Investigative [5]
Papillary renal cell carcinoma DCQTJUY ACHN Investigative [5]
Colon adenocarcinoma DCQS7U0 COLO 205 Investigative [6]
Invasive ductal carcinoma DC9MV0H HS 578T Investigative [6]
Malignant melanoma DC8HW9K LOX IMVI Investigative [1]
Malignant melanoma DCQ9NIE UACC62 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.